Skip to main content

Table 2 Response to artemether–lumefantrine treatment

From: Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda

Characteristic Age Total (n = 61)
<5 years (n = 49) ≥5 years (n = 12)
Fever (≥37.5 °C) persistence [n (%)]    
 Day 1 11 (22.4) 1 (8.3) 12 (19.7)
 Day 2 3 (6.1) 0 3 (4.9)
 Day 3 0 0 0
Parasite persistence    
 Microscopy [n (%)]    
  Day 1 40 (81.6) 11 (91.7) 51 (83.6)
  Day 2 13 (26.5) 5 (4.2) 18 (29.5)
  Day 3 1 (2.0) 0 1 (1.6)
 PCR [n (%)]    
  Day 1 45 (91.8) 11 (91.7) 56 (91.8)
  Day 2 27 (55.1) 6 (50) 33 (54.1)
  Day 3 11 (22.4) 3 (25) 14 (22.9)
 Gametocyte persistence [n (%)]    
  Day 1 4 (8.2) 1 (8.3) 5 (8.2)
  Day 2 3 (6.1) 1 (8.3) 4 (6.6)
  Day 3 3 (6.1) 1 (8.3) 4 (6.6)
 28-day WHO treatment outcome [n (%)]    
  Early treatment failure 0 0 0
  Late clinical failure 2 (4.1) 1 (8.3) 3 (4.9)
  Late parasitological failure 0 0 0
  Adequate clinical and parasitological response 47 (96.0) 11 (91.7) 58 (95.1)
 Cure rate [n (%)]    
  PCR unadjusted 47 (96.0) 11 (91.7) 58 (95.2)
  PCR adjusted 47 (96.0) 11 (91.7) 58 (95.2)
  1. PCR polymerase chain reaction, WHO World Health Organization